What is the latest price for a box of Ribociclib?

As a CDK4/6 inhibitor, Ribociclib plays an important role in the treatment of breast cancer. Its main indication is for patients with hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, and is often used in combination with aromatase inhibitors or fulvestrant. For premenopausal and perimenopausal women, a combination luteinizing hormone-releasing hormone (LHRH) agonist is needed. The core value of Riboxiclib is to block cancer cell proliferation signals, thereby delaying disease progression and improving patients' quality of life.

In China, the original drug Riboxil has been launched and included in the medical insurance catalog, reducing the financial burden on patients. The common specifications are200mg*63 tablets, and the price per box is about more than 4,000 yuan. After reimbursement by medical insurance, the actual payment amount dropped significantly, allowing more patients to afford long-term treatment. For many patients, the implementation of this policy has provided practical help in making targeted drugs more accessible.

In overseas markets, the selling price of Ribociclib varies greatly depending on countries and regions. For example, the common specifications of original research drugs on the market in Europe are 200 mg 21 tablets, 200 mg 42 tablets, and 200 mg 63 tablets. The price of each box may be more than 20,000 yuan, which is significantly higher than that in China. This also illustrates the importance of domestic medical insurance negotiations in reducing drug costs. In the Indian market, there is a cheaper version of the original drug. Each box is priced at about more than 3,000 yuan, but the price will fluctuate due to different exchange rates and channels. At the same time, generic drugs of Riboxil have been launched in some overseas regions, and the ingredients of the drugs are basically the same. Taking the 200mg 21 tablets produced in Laos as an example, the price per box may be more than 1,000 yuan, making it a choice for some patients when looking for alternatives.

Overall, the indication for ribociclib is very clear, namely targetingHR+/HER2- advanced or metastatic breast cancer. At the price level, the accessibility advantage after domestic medical insurance is significant, allowing more patients to obtain long-term standardized treatment.

Reference materials:https://us.kisqali.com/